European pharma companies warned the European Commission president that US tariffs could expedite the industry's shift away from Europe and toward the United States. The pharma trade lobby called for rapid action to mitigate the risk of an exodus to the US. They also emphasized the need for changes in the EU's regulatory framework and intellectual property provisions.